XML Print


Abstract:  
Background: The let-7 family especially let-7f has essential impacts on biological processes. However, biological and molecular functions of let-7 in lung cancer pathogenesis have been remained unclear yet. We aimed to investigate the expression level of let-7f and its candidate target genes both in lung cancer tissues and A549 cell line. Methods: In the present study, firstly, we used bioinformatics databases for selecting candidate target genes of let-7f. Then, the relative gene and protein expressions of let-7f and its target genes including HMGA2, ARID3B, SMARCAD1, and FZD3 were measured in lung tissues of non-small cell lung cancer (NSCLC) patients and A549 cell line using qRT-PCR and western blotting. The electroporation method was used for transfection of A549 cells with let-7f mimic and microRNA inhibitor. The impact of let-7f transfection on the viability of A549 cells was assessed using MTT assay. The expression data of studied genes was analyzed by proper statistical tests. Results: We found significant down-regulated expression level of let-7f-5p (P=0.0013) and up-regulated level of the HMGA2 and FZD3 in NSCLC cases (P<0.05). In A549 cells, after transfection with let-7f mimic, the expression of both mRNA and protein levels of HMGA2, ARID3B, SMARCAD1, and FZD3 decreased. Also, overexpression of let-7f significantly inhibited the A549 cell’s proliferation and viability (P=0.017). Conclusion: The statistical analysis exhibited the high value of let-7f and HMGA2 as biomarkers for NSCLC. The let-7f as a major tumor suppressor regulatory factor via direct targeting genes such as HMGA2 inhibits lung cancer cell’s viability and proliferation, and it could be used for the early diagnostic marker in NSCLC.
     
Type of Study: Full Length | Subject: Cancer Biology

Add your comments about this article : Your username or Email:
CAPTCHA

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2022 CC BY-NC 4.0 | Iranian Biomedical Journal

Designed & Developed by : Yektaweb